Fungal Species: Psilocybe natalensis

The Effectiveness of Microdosed Psilocybin in the Treatment of Neuropsychiatric Lyme Disease: A Case Study

mycolabadmin

A 70-year-old man suffering from severe depression and anxiety caused by chronic Lyme disease and related tick-borne infections found relief after taking small doses of psilocybin mushrooms three times a week. Within days of starting treatment, his mood improved dramatically, and he remained symptom-free for two years. This case suggests that psilocybin’s ability to reduce inflammation in the brain may help patients with infectious-caused psychiatric conditions who cannot tolerate standard medications.

Read More »

The Effect of Combined Treatment of Psilocybin and Eugenol on Lipopolysaccharide-Induced Brain Inflammation in Mice

mycolabadmin

This study tested whether psilocybin (an active compound from magic mushrooms) combined with eugenol (a natural compound from cloves) could reduce brain inflammation in mice. Researchers gave mice a substance that triggers inflammation in the brain and then treated them with these compounds before or after the inflammation started. The combination treatment, especially at a 1:50 ratio of psilocybin to eugenol, significantly reduced multiple inflammatory markers in the brain, suggesting this combination could potentially be helpful for treating brain inflammation-related conditions.

Read More »

DNA Authentication and Chemical Analysis of Psilocybe Mushrooms Reveal Widespread Misdeterminations in Fungaria and Inconsistencies in Metabolites

mycolabadmin

Researchers examined museum specimens of magic mushrooms and found that many are mislabeled and don’t reliably contain the psychoactive compounds they should. The study shows that psilocybin breaks down unpredictably during storage, and these mushrooms contain thousands of unknown chemical compounds. These findings suggest that current regulations and our understanding of these mushrooms need significant updates.

Read More »

Chemical Composition and Biological Activities of Psilocybe Mushrooms: Gaps and Perspectives

mycolabadmin

This review examined research on Psilocybe mushrooms and their chemical compounds, particularly psilocybin and psilocin, which show promise for treating depression and anxiety. The authors found that while these psychoactive compounds have been extensively studied, many other chemical substances in these mushrooms remain unexplored. Additionally, preliminary studies suggest these mushrooms may have antimicrobial and antioxidant properties, though more research is needed. The review highlights significant gaps in understanding the full potential of Psilocybe mushrooms for medical applications.

Read More »
Scroll to Top